The 14 most recent market catalysts affecting $VRTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 75
Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug
Vertex Pharmaceuticals announced encouraging Phase 2b results for inaxaplin, a drug targeting APOL1-mediated kidney disease (AMKD). The data showed significant reductions in protei…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 85
Vertex Pharmaceuticals shares are trading higher after the company announced results from a study of its inaxaplin candidate that showed a reduction in urine albumin to creatinine ratio at week 13 and was generally safe and well tolerated.
The positive clinical trial results for Vertex Pharmaceuticals' inaxaplin candidate are a significant corporate catalyst. The reduction in urine albumin to creatinine ratio, couple…
Sep 15, 2026
Corporate Catalyst
Neutral
Impact 55
Virtuix Announces Sale Of Omni One Systems To The U.S. Department Of Veterans Affairs; Terms Not Disclosed
Virtuix has secured its first sale of Omni One virtual reality systems to the U.S. Department of Veterans Affairs, specifically for deployment at the Valor Center in Detroit. This …
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 65
Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target
Morgan Stanley analyst Terence Flynn has reinstated an 'Overweight' rating on Vertex Pharmaceuticals (VRTX) and announced a $665 price target. This action signals a strong belief i…
Aug 25, 2026
Corporate Catalyst
Neutral
Impact 65
Live On CNBC, Karen Firestone Announces Bought Vertex Pharmaceuticals
This announcement serves as a positive catalyst for Vertex Pharmaceuticals (VRTX) due to the 'smart money' endorsement from Karen Firestone, a respected figure in finance. While no…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565
Truist Securities analyst Danielle Brill has maintained a 'Buy' rating on Vertex Pharmaceuticals (VRTX) and raised the price target from $560 to $565. This action signals continued…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550
TD Cowen analyst Phil Nadeau has maintained a 'Buy' rating on Vertex Pharmaceuticals (VRTX) and raised the price target from $525 to $550. This action signals continued bullish sen…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 75
Vertex shares are trading lower after multiple analyst firms lowered their respective price targets on the stock.
This headline signals a negative sentiment shift for Vertex Pharmaceuticals, driven by professional analysts re-evaluating the stock's potential. Lowered price targets often preced…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $595
This filing discloses that Cantor Fitzgerald analyst Carter Gould has maintained an 'Overweight' rating on Vertex Pharmaceuticals (VRTX) and raised the price target from $590 to $5…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 75
Vertex Pharmaceuticals Raises FY2026 Sales Guidance from $12.950B-$13.100B to $13.100B-$13.200B vs $13.065B Est
Vertex Pharmaceuticals announced an upward revision to its FY2026 sales guidance, moving from $12.950B-$13.100B to $13.100B-$13.200B. This is significant as the new lower bound ($1…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 75
Vertex Pharmaceuticals Q2 Adj. EPS $4.73, Inline, Sales $3.334B Beat $3.232B Estimate
Vertex Pharmaceuticals' Q2 earnings report shows a mixed but generally positive picture. While adjusted EPS met expectations, the significant beat in sales by 3.15% and a 12.45% ye…
Jul 21, 2026
Corporate Catalyst
Bearish
Impact 75
Vertex shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight rating and lowered its price target from $19 to $15.
This headline represents a significant corporate catalyst for Vertex Pharmaceuticals. Analyst downgrades from major investment banks like Morgan Stanley often trigger immediate neg…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 60
UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $585
UBS analyst Michael Yee maintained a 'Buy' rating on Vertex Pharmaceuticals and raised the price target from $545 to $585. This action signals continued confidence in the company's…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $560
Truist Securities analyst Danielle Brill maintained a 'Buy' rating on Vertex Pharmaceuticals (VRTX) and raised the price target from $542 to $560. This action signals an analyst's …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.